Baxter International (BAX) : 11 analysts are covering Baxter International (BAX) and their average rating on the stock is 2.94, which is read as a Hold. 1 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 2, which recommends a Buy affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 9 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Baxter International (BAX) : The consensus price target for Baxter International (BAX) is $50.29 for the short term with a standard deviation of $4.79. The most optimist securities analyst among the 7 who monitor the stock believes that the stock can reach $60, however, the pessimist price target for the company is $46.
Baxter International Inc. has dropped 0.54% in the last five trading days, however, the shares have posted positive gains of 4.08% in the last 4 weeks. Baxter International Inc. is up 10.23% in the last 3-month period. Year-to-Date the stock performance stands at 26.51%. Baxter International (NYSE:BAX): The stock was completely flat for the day, closing at $47.98 on Tuesday. The flat closing masks the intraday volatility in the stock. After opening at $48.07, the stock touched an intraday high of $48.35 and a low of $47.94. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $47.98. The total trading volume on Tuesday was 2,280,837.
Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.